Company news

Heron Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Heron Therapeutics Announces Cost Reduction Plan and Restructuring

July 23, 2023

Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

June 22, 2023

Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer

June 11, 2023

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates

May 10, 2023

Heron Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

May 3, 2023

Heron Therapeutics Announces Commercial Leadership Changes

April 19, 2023

Heron Therapeutics Announces Presentation at 22nd Annual Needham Virtual Healthcare Conference

April 16, 2023

Heron Therapeutics Announces New CEO and Board Chairman

April 2, 2023

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates

March 22, 2023

Heron Therapeutics Announces Centers for Medicare & Medicaid Services (CMS) Granted Pass-through Payment Status for APONVIE™, Effective April 1, 2023

March 12, 2023

Heron Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 23, 2023

March 9, 2023

Heron Therapeutics Announces U.S. Commercial Launch of APONVIE™ for the Management of Postoperative Nausea and Vomiting in Adults

March 5, 2023

Heron Therapeutics Announces Presentation at 43rd Annual Cowen Healthcare Conference

February 26, 2023

Heron Therapeutics Enters into Cooperation Agreement with Rubric Capital and Velan Capital

February 21, 2023

Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises

January 8, 2023

Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF® and Provision in Newly Passed Congressional Bill Anticipated to Provide Separate Reimbursement Outside of the Packaged Surgical Payment for ZYNRELEF

December 28, 2022

Heron Therapeutics Announces Virtual Presentation at Evercore ISI 5th Annual HealthCONx Conference

November 20, 2022

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate Updates

November 7, 2022

Heron Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

October 31, 2022

Heron Therapeutics Announces U.S. FDA Approval of APONVIE™ (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV)

September 15, 2022

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Highlights Recent Corporate Updates

August 8, 2022

Heron Therapeutics Announces $76.5 Million Private Placement Financing

August 8, 2022

Heron Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

August 1, 2022

Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability

June 29, 2022

Heron Therapeutics Announces Publication Showing ZYNRELEF® as the Foundation of a Perioperative Non-Opioid Multimodal Analgesic Regimen Reduced Severe Pain and Opioid Use in Patients Undergoing Total Knee Arthroplasty

June 13, 2022

Heron Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference

May 25, 2022

Heron Therapeutics Presents ZYNRELEF® Data at the Society for Obstetric Anesthesia and Perinatology 54th Annual Meeting

May 15, 2022

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Recent Corporate Updates

May 8, 2022

Heron Therapeutics to Report First Quarter 2022 Financial Results on Monday, May 9, 2022

May 2, 2022

Heron Therapeutics to Present at the 21st Annual Virtual Needham Healthcare Conference

April 4, 2022

Heron Therapeutics Secures Pass-through Payment Status for ZYNRELEF® from Centers for Medicare & Medicaid Services, Expanding Separate Reimbursement into the Hospital Outpatient Setting of Care

March 24, 2022

Heron Therapeutics Announces Approval of ZYNRELEF® by Health Canada for the Management of Postoperative Pain

March 16, 2022

Heron Therapeutics to Present at 42nd Annual Cowen Healthcare Conference

March 1, 2022

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Recent Corporate Updates

February 27, 2022

Heron Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

February 21, 2022

Heron Therapeutics Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF®

December 8, 2021

Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA

November 17, 2021

Heron Therapeutics to Present at Upcoming Investor Conferences

November 10, 2021

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Recent Corporate Updates

November 2, 2021

Heron Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 3, 2021

October 27, 2021

Heron Therapeutics Announces Filing of a Supplemental New Drug Application for Significant Expansion of ZYNRELEF® Indication Statement Based on Successful Outcome of FDA Type C Meeting

October 3, 2021

Heron Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference

September 20, 2021

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Recent Corporate Updates

August 8, 2021

Heron Therapeutics Announces Publication of Results from HOPE (Helping Opioid Prescription Elimination), Showing ZYNRELEF™ Minimizes the Need for Opioids in a Real-World Setting, With 95% of Patients Experiencing an Opioid-free Recovery

July 27, 2021

Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™

July 20, 2021

Heron Therapeutics Announces 340B Prime Vendor Contract with Apexus for ZYNRELEF™

July 5, 2021

Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF™ for the Management of Postoperative Pain for up to 72 Hours

June 30, 2021

Heron Therapeutics to Present at the 2021 Jefferies Virtual Investor Conference

May 24, 2021

Heron Therapeutics Announces $150 Million Convertible Debt Financing

May 24, 2021

Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours

May 12, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 42 decks. Every deck is listed under its year.